Document text
Principal Investigator: D. Rebecca Prevots
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2022
Award: $11,997
Funding agency: National Institute of Allergy and Infectious Diseases
Background
Prior research has shown variability in household secondary attack rates (SAR) and transmission risks of SARS-CoV-2, which remains poorly understood. To address these questions, we conducted a household serologic study nested within a larger prospective cohort study of SARS-CoV-2 in Costa Rica.
Methods
Household contacts of SARS-CoV-2 positive index cases were enrolled. Demographic, clinical, and behavioral information was collected from cases and their household contacts. Blood specimens were collected from contacts within 30-60 days of index case diagnosis and serum was tested for presence of spike and nucleocapsid SARS-CoV-2 IgG antibodies. SARS-CoV-2 infection among contacts was defined based on the presence of both spike and nucleocapsid antibodies. A chain binomial model was fitted to jointly estimate household and community risk of infection and assess transmission heterogeneities.
Findings
Overall, 719 household contacts of 304 household index cases were enrolled from November 21, 2020, through July 31, 2021. The estimated household secondary attack rate was 32% and the average community infection risk was 19%. Not sharing a bedroom with the index case reduced the risk of household transmission by 71% (OR= 0.29 with 95%CI:0.13-0.53), and mask wearing by the index case reduced the risk by 62% (OR= 0.38 with 95%CI: 0.12-0.83). The estimated distribution of household SAR was highly heterogeneous across index cases, with 36% of index cases responsible for 80% of secondary cases. This heterogeneity was partially explained by adoption of prevention measures within the household
Interpretation
We have identified practical and effective non-pharmaceutical prevention measures, which account for a major source of transmission heterogeneity within the household.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><7S Gamma Globulin><Active Follow-up><Address><Adoption><Age><Americas><Antibodies><Antibody Response><Behavioral><Binomial Model><Blood Sample><Blood Serum><Blood specimen><COVID crisis><COVID epidemic><COVID infected patient><COVID pandemic><COVID patient><COVID positive patient><COVID-19><COVID-19 antibody><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infected patient><COVID-19 infection><COVID-19 pandemic><COVID-19 patient><COVID-19 positive><COVID-19 positive patient><COVID-19 positivity><COVID-19 public health crisis><COVID-19 transmission><COVID-19 virus><COVID-19 virus transmission><COVID19><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 pandemic><COVID19 patient><COVID19 positive><COVID19 positive patient><COVID19 positivity><COVID19 public health crisis><COVID19 virus><CV-19><CV19><Cancers><Cervical><Clinical><CoV-2><CoV2><Collaborations><Communities><Complex><Costa Rica><Costa Rican><Crowding><Diagnosis><Diagnostic Findings><Disease><Disorder><Enrollment><Goals><HPV Vaccine><Health Care Systems><Healthcare Systems><Heterogeneity><History><Household><Human Papilloma Virus Vaccine><Human papillomavirus Vaccine><IgG><Immune response><Immunoglobulin G><Immunological response><Immunology><Individual><Infection><Infrastructure><Interview><Malignant Neoplasms><Malignant Tumor><Masks><Medical><Methods><NCI Organization><National Cancer Institute><Nucleocapsid><Patient Self-Report><Prevention Measures><Prospective Studies><Prospective cohort study><Randomization trial><Recording of previous events><Research><Research Institute><Risk><Risk Factors><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 antibody><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 patient><SARS-CoV-2 positive><SARS-CoV-2 positive patient><SARS-CoV-2 positivity><SARS-CoV-2 transmission><SARS-CoV2><SARS-CoV2 antibody><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Self-Report><Serology><Serum><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 positive><Severe acute respiratory syndrome coronavirus 2 positivity><Severe acute respiratory syndrome related corona virus 2><Signs and Symptoms><Socio-economic status><Socioeconomic Status><Source><Testing><Transmission><Vaccines><Viral><Wuhan coronavirus><active followup><ages><antibody against COVID-19><antibody against SARS-CoV-2><antibody against SARS-CoV2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody to COVID-19><antibody to SARS-CoV-2><antibody to SARS-CoV2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><base><cohort><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 antibody><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 patient><coronavirus disease 2019 positive><coronavirus disease 2019 positive patient><coronavirus disease 2019 positivity><coronavirus disease 2019 public health crisis><coronavirus disease 2019 transmission><coronavirus disease 2019 virus><coronavirus disease 2019 virus transmission><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease infected patient><coronavirus disease pandemic><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 patient><coronavirus disease-19 virus><coronavirus infectious disease-19><coronavirus patient><enroll><follow up><follow-up><followed up><followup><hCoV19><host response><immune system response><immunoresponse><indexing><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><infection rate><infection risk><malignancy><nCoV2><neoplasm/cancer><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><primary end point><primary endpoint><protective efficacy><randomized trial><rate of infection><secondary infection><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 transmission><sex><socio-economic position><socioeconomic position><transmission process><transmitted COVID-19><transmitted SARS-CoV-2><transmitted coronavirus disease 2019><transmitted severe acute respiratory syndrome coronavirus 2>